Rostock International Parkinson's Disease Study (ROPAD) (ROPAD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03866603|
Recruitment Status : Recruiting
First Posted : March 7, 2019
Last Update Posted : January 6, 2021
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||10000 participants|
|Official Title:||Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study|
|Actual Study Start Date :||May 30, 2019|
|Estimated Primary Completion Date :||December 31, 2021|
|Estimated Study Completion Date :||December 31, 2021|
Parkinson´s disease individuals
The participants that are clinically diagnosed with Parkinson's disease
Family member of a participant with LRRK2 parkinsonism
The first and second degree family members of the ROPAD Study participants with LRRK2 parkinsonism
High risk population
Populations at high risk such as Ashkenazi Jewish and Arab Berber
- To identify 1,500 LRRK2-positive participants [ Time Frame: 2 years ]The participants fulfilling the eligibility criteria will be enrolled into the Study and genetically tested for LRRK2 hotspot mutations and the whole GBA gene will be sequenced.
- To identify 1,500 non-LRRK2 PD participants [ Time Frame: 2 years ]Participants with negative results for LRRK2 hotspots and GBA, clinically diagnosed for PD and are willing to participate in further genetic screening, 68 PD associated genes will be sequenced.
- Establishment of candidate LRRK2-positive biomarkers in the LRRK2-positive cohort [ Time Frame: 2 years ]LRRK2-positive samples will be validated for the identification of potential biomarkers (based on MS/MS-Spectroscopy) and compared with a merged control sample in order to establish a LRRK2 specific biomarker.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03866603
|Contact: Volha Skrahina, PhD||+49 (0)email@example.com|
|Contact: Hanaa Gaber, PhD||+49 (0)firstname.lastname@example.org|
|Principal Investigator:||Arndt Rolfs, Prof. Dr.||CENTOGENE GmbH|